Enterprise capital agency Catalio Capital Administration introduced at present the closing of its greater than $400 million Fund IV, as first reported by Bloomberg. The fund will proceed the agency’s thesis of backing healthcare and biotechnology corporations.
The agency was based in 2020 and has made greater than 100 investments, in accordance with Pitchbook. Catalio’s Fund IV, particularly, has backed 16 corporations already, together with the diagnostics firm PinkDX and the drug discovery firm Superluminal Medicines.
The agency beforehand raised a $381 million Fund III in 2020 and a $100 million Fund II in 2019, per Pitchbook.
The biotech market, particularly, has not been resistant to the enterprise downturn of the previous 12 months, adopted by greater rates of interest and a cooler IPO market. The market general raised simply $12 billion final 12 months, a pointy decline from its peak of $152.3 billion in 2023, as reported by Bloomberg.
